显示框
×
CN
|
EN
Home
Our Technology
Frequently Asked Questions
Our Products
IBS Coronary Scaffold
IBS Titan™ Peripheral Scaffold
IBS Angel™ Pulmonary Artery Scaffold
【CE Version】IBS Angel™ Iron Bioresorbable Scaffold System
Our Profile
Industrial News
Certifications
Academic Publications
News
About Us
Our Company
Our Development
Join Us
Contact Us
Home
Our Technology
Frequently Asked Questions
Our Products
IBS Coronary Scaffold
IBS Titan™ Peripheral Scaffold
IBS Angel™ Pulmonary Artery Scaffold
【CE Version】IBS Angel™ Iron Bioresorbable Scaffold System
Our Profile
Industrial News
Certifications
Academic Publications
News
About Us
Our Company
Our Development
Join Us
Contact Us
Our Profile
2019
The IBS project team was spun off from LifeTech, and Biotyx was established
Learn More >
2019
The IBS project team was spun off from LifeTech, and Biotyx was established
Learn More >
2020
IBS products were approved as innovative medical devices by NMPA; 160 million RMB of round A financing led by IDG was introduced
Learn More >
2020
IBS products were approved as innovative medical devices by NMPA; 160 million RMB of round A financing led by IDG was introduced
Learn More >
2021
Approved as a national high-tech enterprise; IBS Angel™ was approved for Malaysian registration
Learn More >
2021
Approved as a national high-tech enterprise; IBS Angel™ was approved for Malaysian registration
Learn More >
2022
IBS® Coronary Scaffold completed Phase II clinical trial enrollment
Learn More >
2022
IBS® Coronary Scaffold completed Phase II clinical trial enrollment
Learn More >
2023
IBS Angel™ obtained the EU CE MDR registration certificate; IBS® Coronary Scaffold completed Phase III clinical trial enrollment; introduced more than 200 million RMB of round B financing
Learn More >
2023
IBS Angel™ obtained the EU CE MDR registration certificate; IBS® Coronary Scaffold completed Phase III clinical trial enrollment; introduced more than 200 million RMB of round B financing
Learn More >
2024
IBS® released Phase II and III clinical 1-year follow-up data during the EuroPCR 2024 and TCT 2024 conferences; approved to lead the Ministry of Science and Technology's key R&D project
Learn More >
2024
IBS® released Phase II and III clinical 1-year follow-up data during the EuroPCR 2024 and TCT 2024 conferences; approved to lead the Ministry of Science and Technology's key R&D project
Learn More >
2025
IBS® Coronary Scaffold submitted NMPA registration application
Learn More >
2025
IBS® Coronary Scaffold submitted NMPA registration application
Learn More >
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024-11-01
07:00:00
More
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024-05-20
07:00:00
More
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024-05-20
07:00:00
More
NEWS
Latest news about us
More >
NEWS
Latest news about us
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024 TCT | Academician Runlin Gao's team announced the one-year follow-up results of Biotyx's IBS™ Coronary Scaffold Phase III clinical study safety and effectiveness were further confirmed
2024-11-01
07:00:00
More
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024EuroPCR| Academician Runlin Gao's team announced the one-year follow-up results of the Phase II clinical study of Biotyx's IBS™ Coronary Scaffold
2024-05-20
07:00:00
More
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024EuroPCR │Biotyx's IBS™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System was selected as the "Best Highlight" and new trend of PCI at the EuroPCR conference
2024-05-20
07:00:00
More
More >
Home
Product
News
About Us
Technology
